Emergent BioSolutions was awarded a contract modification valued at approximately $24 million from the U.S. government to supply CYFENDUS.

Public source

Publisher name

Public post

Today Emergent announced it has been awarded a contract modification valued at approximately $24 million from the U.S. government to supply CYFENDUS® (Anthrax Vaccine Ad…

Log in to read the full post

Company

Emergent BioSolutions

We help prepare for today's challenges and tomorrow's threats.

Industry
Biotechnology Research
Location
Gaithersburg, US
Company size
1,001–5,000 employees

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Please note: It has come to our attention that there may be people posing as Emergent recruiters and hiring managers online, offering fraudulent opportunities to job seekers. Emergent will never ask for any financial commitment from a candidate as a pre-employment requirement. Learn more about recruitment fraud and how to protect yourself here: https://bit.ly/recruitment-fraud

See more

Latest activity

5 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.